UNSPSC 51432001: Sitaxentan

This classification denotes an endothelin-1 protein receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J9QH779MEM. European Medicines Agency schedules Sitaxentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22917. Sitaxentan generally arises in the molecular formula C18H15CLN2O6S2.

The term SITAXENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule sitaxentan under HS 29350090 and SITC 51580. As of Q4 2014, SITAXENTAN remains the US FDA Preferred Term for this commodity. Sitaxentan bears US NLM identifiers UMLS ID C1704271 and NCI Concept Code C73038. SMILES: CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2.

UNSPSC 51432001 Sitaxentan, a Commodity code, reflects state and local procurement of advanced pharmaceutical products for emergency medical services, public health programs, and multistate cooperative purchasing initiatives. Recent opportunities show state and local governments buying generic pharmaceuticals, specialty medications for emergency response, and over-the-counter products through both direct procurement and cooperative purchasing vehicles. The City of Tampa's Fire Rescue Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of issuing bodies active under this code—municipal emergency services, state health agencies, and multistate cooperative procurement organizations that aggregate purchasing across member jurisdictions.

Activity appears concentrated in the South and Midwest. The City of Tampa solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) for Hillsborough County Fire Rescue, specifying four medication line items including Labetalol, Epinephrine, Adenosine, and Diltiazem, with an estimated contract value of $40,000 and a one-year term plus renewal options; the RFP included a 5 percent Small Local Business Enterprise (SLBE) bid discount and compliance requirements for OSHA Safety Data Sheets and WCAG 2.2 accessibility standards. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription procurement strategies outside traditional pharmacy benefit manager channels—an exploratory market-intelligence phase preceding formal solicitation. MMCAP (Minnesota Department of Administration) issued a broader RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across multiple states, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with a two-year initial term and weighted evaluation favoring price competitiveness at 75 percent of the score.